Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
Newly Appointed Company Head Speaks For First Time At J.P. Morgan Conference
Executive Summary
On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.
You may also be interested in...
Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars
Teva’s president and CEO Kåre Schultz provided fresh long-term financial targets for the company in the wake of the firm agreeing in principle to settle opioid-related claims in the US – but will the architect of Teva’s restructuring remain beyond his current November 2023 contract?
Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025
European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.
Amgen’s $27.8bn Horizon Takeover Stipulates Biosimilar Restrictions
The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.